Alpha1-antitrypsin (AAT) is the archetypal protein of the serine proteinase inhibitor (SERPIN) superfamily. AAT is synthesized in hepatocytes and macrophages and protects the lower respiratory tract from proteolytic degradation by neutrophil elastase ([@Perlinoetal1987]). This protein is encoded by a highly polymorphic locus, PI (for Proteinase Inhibitor), that consists of seven exons dispersed over 12.2 kb on chromosome 14q31-32.3 (Li et *al.,* 1998). The two parental PI genes are codominantly expressed and dictate the AAT serum level (Brantly et *al.,* 1991). The most common PI allele is designated PI\*M and has a gene frequency of 0.95. Homozygosity of the PI\*M allele results in AAT plasma concentrations ranging from 150 to 350 mg/dL, which provides a sufficient protease/antiprotease balance to protect lung tissues. The most frequent deficient variants are PI\*S (p.E264V) and PI\*Z (p.E342L). PI\*S produces approximately 60% of PI\*M alpha1-antitrypsin and the PI\*Z allele produces 10%-15% of normal AAT levels. Other rarer deficiency states arising from null alleles result in no detectable AAT protein ([@Crystal1990]). The major clinical consequence of AAT deficiency (AATD) is a high risk of early onset panlobular emphysema and, to a lesser extent, chronic liver disease and cirrhosis ([@MahadevaandLomas1998]). Current gene frequency data indicate that AATD is one of the most common inherited disorders worldwide ([@deSerresetal2007]).

In this report, we provide additional sequence data for AAT based on the characterization of a novel AAT mutation discovered in a Tunisian patient with chronic obstructive pulmonary disease (COPD).

A 53-year-old man diagnosed with pulmonary emphysema was enrolled in a targeted AATD screening program run by the Pneumology Department of Ibn Eljazzar Hospital in Kairouan (central Tunisia). Based on a previously described algorithm (Denden et *al.,* 2009), all patients with obstructive lung disease and an AAT level \< 150 mg/dL (threshold value) attended at this unit are screened for AATD. In this case, the AAT plasma concentration was 132 mg/dL, as measured using an immune turbidimetric assay (Denden et *al.,* 2009). The patient, an ex-smoker with a history of 28 pack-years, presented the common symptoms of airway obstructive disease, *i.e.*, breathlessness, cough, wheeze and phlegm. These symptoms began at 50 years of age. During a two-year follow-up, the patient showed increasing dyspnea and weight loss. An intradermal skin test and the quantification of total IgE (22.5 IU/mL) indicated that there was no atopy. At his first presentation, chest radiographs showed hyperinflation with an anterior diaphragmatic angle of 107 degrees in lateral view and a retrosternal airspace of 5.2 cm. Decreased lung markings and bullae were localized in the lower zones. Chest computed axial tomography confirmed the emphysematous state of the lower lobe and the presence of pulmonary parenchymal destruction seen as large areas of hypolucency and the presence of bullae. Baseline lung function tests were consistent with the onset of severe COPD: the forced expiratory volume in 1 s (FEV1) was 28% of the predicted value and the FEV1/FVC (forced vital capacity) ratio was 70%. After bronchodilator inhalation, the FEV1 improved 4.8% relative to the baseline value. During the follow-up, lung function impairment, assigned by the annual decline in FEV1 (ΔFEV1), was 213 mL/year.

Blood samples were collected for analysis after obtaining the patients informed consent and the investigation was approved by the local Ethics Committees of the institutions involved. DNA was isolated from whole peripheral blood using a standard phenol-chloroform method. Genotyping by RFLP-PCR was used to detect the most prevalent AATD mutations (S and Z) ([@Dendenetal2009]). This analysis does not report any S or Z AAT allele. Sequencing of the AAT gene coding regions as previously described ([@Dendenetal2009]) revealed a novel point mutation at c.97 T → C ([Figure 1](#fig1){ref-type="fig"}). This substitution led to the replacement of phenylalanine by leucine (F33L). Since the mutation was found in the heterozygous state, the PCR product of exon II of the SERPINA1 gene was cloned to identify the allele with the mutated base. Cloning was done using a TOPO-TA cloning kit (Invitrogen Corporation, Carlsbad, CA). The sequencing of positive clones confirmed the presence of the c.97 T → C point mutation on the PI\*M2 (c.302 G → A) allele ([Figure 2](#fig2){ref-type="fig"}).

Although the mutation occurred in the heterozygous state, mild AATD, usually observed in subjects carrying only one deficient allele, could explain the disease. Indeed, a meta-analysis of previous studies indicated an increase in the risk of COPD in PI\*MZ heterozygotes ([@Hershetal2004]). The serum AAT level in this patient (132 mg/dL) was within the normal AAT range of the Tunisian population \[120-280 mg/dL\] (Denden et *al.,* 2008). However, the patient\'s heterozygous state meant that the expression of a normal allele (PI\*M1) could have masked any deficiency arising from the mutated allele. Additional investigations were needed to elucidate this deficiency but, unfortunately, none of the patient\'s family members was available for further study.

To circumvent this limitation, computational methods were used to assess whether the mutation was detrimental to the protein structure and/or function. Changes in the stability of the mutant protein compared to the wild type protein were predicted using the Auto-Mute server ([@MassoandVaisman2008]). SIFT (Sorting Intolerant from Tolerant) software ([@NgandHenikoff2002]) was used to predict tolerance to the causal non-synonymous SNP (nsSNP) on the basis of sequence conservation in the protein family. The PolyPhen bioinformatic algorithm ([@Ramenskyetal2002]) was used to predict the influence of the mutation based on data derived from structural parameters, functional annotations and evolutionary information, and the HybridMeth algorithm ([@Capriottietal2006]) was used to predict the effect of the nsSNP based on evolutionary information. The p.F33L mutant was predicted to be 1.41 kcal mol^-1^ less stable than the wild type protein (PDB ID: 1atu). SIFT software showed that the phenylalanine at position 33 was highly conserved in the protein family (score of 0.00), while the HybridMeth algorithm favored a disease-associated nsSNP with a reliability index of 7. PolyPhen predicted that the p.F33L mutation was possibly deleterious to AAT (PSIC score difference of 1.882). The PolyPhen decision tree indicated that substitution of the buried amino acid F by L at position 33 in the AAT-A-α-helix led to a reduction in side chain volume of 23 Å^3^ and the creation of a cavity. Cavities in the protein hydrophobic core are very likely to disturb the tridimensional structure and folding of AAT. *In silico* analysis with known mutations was used to assess the accuracy of the predictions and confirmed that the computational analyses based on evolutionary, structural and functional information were in agreement with previous findings *in vivo* and *in vitro* ([Table 1](#t1){ref-type="table"}). A neutral effect was predicted for mutations associated with a normal AAT level: the common AAT mutations PI\*M2 (R101H) and PI\*M3 (E376D) apparently had no effect on the protein ([Table 1](#t1){ref-type="table"}). Mutations associated with a low AAT level were predicted to be damaging: AATD, observed in the most prevalent deficiency variants PI\*S (E264V) and PI\*Z (E342L), was attributed to a change in hydrophobicity and charge at buried sites of the protein. The rare allele PI\*M~wurzburg~ (E369S) showed the same abnormality as the F33L mutation, *i.e.*, a 23 Å^3^ reduction in side chain volume ([Table 1](#t1){ref-type="table"}).

![Partial exon II sequence of the *SERPINA1* gene (genomic DNA) reveals a novel c.97 T → C mutation at the heterozygous state.](gmb-33-4-633-gfig1){#fig1}

![Partial exon II sequence of the *SERPINA1* gene (cloned DNA) reveals the presence of c.97 T → C and c.302 G → A substitutions on the same chromosome.](gmb-33-4-633-gfig2){#fig2}

In conclusion, we have described a novel rare PI mutation that is likely to be clinically important, as suggested by computational analyses. Further studies are required to confirm this finding.

The authors thank Dr. Maurizio Luisetti of the Center for Diagnosis of Inherited Alpha1-Antirtypsin Deficiency, Pavia, Italy, for providing laboratory space for Sabri Denden to clone and sequence the AAT variant described in this work.

Associate Editor: Carlos F.M. Menck

###### 

Computational analysis of alpha1-antitrypsin variants.

  Mutation                     Location     Auto-mute   SIFT         HybridMeth    PolyPhen                       
  ---------------------------- ------------ ----------- ------------ ------------- ---------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Normally secreted variants                                                                                      
  R101H                        hD           -0.29       Yes (0.47)   Neutral (6)   1.162      benign              NA
  E376D                        s4B          -0.17       Yes (0.56)   Neutral (7)   0.264      benign              Hydrophobicity change at buried site of 0.78; accN: 0.00
  A34T                         hA           -2.17       Yes (0.06)   Neutral (4)   0.657      benign              Distance to MET 385 of 3.345 Å
  P88T                         hD           -1.32       Yes (0.59)   Neutral (2)   0.937      benign              NA
  A60T                         hB-hC        -1.35       No (0.02)    Neutral (7)   1.001      benign              NA
  G148R                        s1A          -1.14       Yes (0.64)   Neutral (3)   0.631      benign              Charge change at exposed site, accN: 0.83
  E204K                        s4C          -0.89       Yes (0.98)   Neutral (3)   0.134      benign              NA
  L276P                        hH           -2.22       Yes (0.27)   Disease (5)   0.931      benign              Distance to ILE 375B of 3.807 Å
  P362T                        s1C          -1.45       Yes (0.52)   Neutral (8)   1.411      benign              NA
  AAT Deficient variants                                                                                          
  E342L                        s5A          0.87        No (0.00)    Disease (7)   3.190      probably damaging   Hydrophobicity change at buried site of 1.59, accN: 0.03; charge change at buried site
  E264V                        hG           0.32        No (0.03)    Disease (4)   1.773      probably damaging   Hydrophobicity change at buried site of 1.48; LYS 383H distance 2.658 Å; charge change at buried site, accN: 0.03
  R223C                        thIs5A       -1.18       No (0.04)    Disease (3)   0.671      possibly damaging   Cavity creation at buried site of -65 Å^3^; ligand: CIT distance 3.818 Å; hydrophobicity change at buried site of 1.66; charge change at buried site, accN: 0.15
  L41P                         hA           -1.67       No (0.00)    Disease (8)   2.621      probably damaging   Hydrophobicity change at buried site of 1.07, accN: 0.05
  K335E                        s5A          -0.17       No (0.00)    Disease (5)   1.612      possibly damaging   Distance to PHE 384B of 5.913 Å
  M221T                        s4C-s2B      -2.33       No (0.00)    Disease (6)   3.746      probably damaging   Hydrophobicity change at buried site of 1.02, accN: 0.00
  T85M                         hC-hD        0.07        Yes (0.09)   Disease (4)   2.400      probably damaging   Overpacking of 47 Å^3^, accN:0.90
  R39C                         hA           -0.86       No (0.00)    Disease (7)   2.872      probably damaging   Cavity creation at buried site of -65 Å^3^, accN: 0.35
  P369S                        s4B          -1.61       No (0.00)    Disease (3)   1.726      possibly damaging   Cavity creation at buried site of -23 Å^3^, accN: 0.20
  P369L                        s4B          -1.65       No (0.00)    Disease (5)   3.230      probably damaging   Overpacking of 55 Å^3^, accN: 0.20
  D256V                        ts2Bs3B-hG   0.53        Yes (0.11)   Disease (5)   1.698      possibly damaging   Distance to functional site SER 232A of 5.173 Å; distance to LYS 368B of 3. 307Å
  G67E                         hB-hC        -1.02       No (0.00)    Disease (8)   2.760      probably damaging   Overpacking at buried site of 78 Å^3^; hydrophobicity change at buried site of 2.44; Charge change at buried site, accN: 0.00
  A336T                        s5A          -0.26       Yes (0.08)   Disease (2)   0.993      probably damaging   Hydrophobicity change at buried site of 1.08; distance to PHE 384B of 4.320 Å, accN: 0.00
  G225R                        s4C-s2B      -0.48       Yes (0.11)   Disease (2)   0.714      probably damaging   Overpacking at buried site of 133 Å^3^; PRO 361B distance 5.919Å; hydrophobicity change at buried site of 3.3; charge change of a buried site, accN: 0.00
  F33L                         hA           -1.41       No (0.00)    Disease (7)   1.882      possibly damaging   Cavity creation at buried site of -23 Å^3^, accN: 0.00

ΔΔG expected: free energy change of protein stability at 25 °C, pH 7 (kcal mol^-1^) computed using the Auto-Mute server; Tolerance: tolerance to substitution scored using SIFT software; SPBP: sequence and profile based prediction of HybridMeth; RI: reliability index. PSIC difference: Position-Specific Independent Counts score difference between the two amino acids determined using the PolyPhen tool; accN: normed accessible surface area.
